Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model

Area of Science:

• Ototoxicity research
• Translational medicine
• Pharmacology

Background:

• Cisplatin chemotherapy can cause ototoxicity, leading to hearing loss.
• Developing reliable animal models is crucial for studying and preventing cisplatin-induced hearing damage.

Purpose of the Study:

• To establish a multidose cisplatin murine model for ototoxicity research.
• To evaluate the efficacy of intratympanic dexamethasone in preventing cisplatin ototoxicity.

Main Methods:

• CBA/J mice received intraperitoneal cisplatin (2 or 3 mg/kg/day) for 5 or 10 days.
• Auditory brainstem response (ABR) thresholds were measured to assess hearing loss.
• Mice received intratympanic dexamethasone or saline in a controlled study.

Main Results:

• A 5-day regimen of 3 mg/kg/day cisplatin effectively induced hearing threshold elevations with acceptable mortality.
• Significant hearing threshold elevations were observed across all tested frequencies.
• No statistically significant difference in hearing protection was found between intratympanic dexamethasone and saline treatments.

Conclusions:

• Intratympanic dexamethasone demonstrated no otoprotective effect in the developed multidose cisplatin ototoxicity mouse model.
• This finding contrasts with potential benefits observed in single-dose cisplatin ototoxicity models.
• The study highlights the need for further research into effective otoprotective strategies for multidose cisplatin therapy.